Further mechanistic investigations revealed that RHBDD1 contributes to ESCC progression by enhancing cell proliferation (as measured by CCK-8 and EdU assays) and simultaneously inhibiting apoptosis (quantified by annexin V-FITC/PI flow cytometry). Here, RHBDD1 is linked to esophageal squamous cell carcinoma.